Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
ANVISA issues CGMP to Concord Biotech’s Unit I
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Subscribe To Our Newsletter & Stay Updated